Sugi Predict

Sugi Predict / Compounds / SCHEMBL7874089

SCHEMBL7874089

SCHEMBL7874089

CN1CCN2C(=O)CCC2C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 4/20 0.41
▸ HTR2A P28223 3/20 0.41
▸ HTR2C P28335 3/20 0.41
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNB4 P30926 1/20 0.37
▸ CHRNA3 P32297 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ PDCD1LG2 Q9BQ51 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SRD5A1 P18405 1/20 0.33
▸ CNR1 P21554 2/20 0.32
▸ CNR2 P34972 2/20 0.32
▸ AKR1C3 P42330 1/20 0.32
▸ AKR1C2 P52895 1/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.31
▸ BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23525931 1.00 HTR2B (0.41) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL21740358 1.00 HTR2B (0.41) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL21739494 0.89 CHRNB2 (0.45) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL21739324 0.89 CHRNB2 (0.45) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL12267931 0.89 CHRNB2 (0.45) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL15185053 0.82 CHRNB2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12309469 0.81 KDM5A (0.42) HTR2BHTR2AHTR2CCHRNB2CHRNB4
SCHEMBL10210762 0.79 JAK2 (0.41) HTR2BCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL21946382 0.79 JAK2 (0.41) HTR2BCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL10210786 0.79 JAK2 (0.41) HTR2BCHRNB2CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312482-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-10-05 — — US claimed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 — — US claimed
EP-4188383-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-06-07 — — EP claimed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 — — US claimed
EP-4076418-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-10-26 — — EP claimed
CN-115135315-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2022-09-30 — — CN claimed
WO-2022026465-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-02-03 — — WO claimed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 — — US claimed
WO-2021127429-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2021-06-24 — — WO claimed
US-20230312482-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-10-05 — — US disclosed
EP-4223754-A1 COMPOUND AS AKT KINASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-09 — — EP disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 — — US disclosed
EP-4188383-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
WO-2023072273-A1 POLYCYCLIC COMPOUND AS CBL-B INHIBITOR 先声再明医药有限公司 2023-05-04 — — WO disclosed
US-20090054644-A1 PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-02-26 — — US disclosed
US-20090054644-A1 PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-02-26 — — US disclosed
US-20080269208-A1 Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders KaNDy Therapeutics Limited (GB) 2008-10-30 — — US disclosed
US-20080045718-A1 Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives MERCK SHARP & DOHME CORP. 2008-02-21 — — US disclosed
US-20070099914-A1 Piperidine Derivatives NERRE THERAPEUTICS LIMITED (GB) 2007-05-03 — — US disclosed
US-7189713-B2 Piperidine derivatives GLAXO GROUP LIMITED (GB) 2007-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099914-A1 Piperidine Derivatives PTGES2, NFKBIA, PTGS2 HTR2B 1064/4885HTR2A 1432/4885HTR2C 1390/4885
US-20230312482-A1 SOS1 INHIBITORS SOS1, SOS2, SOST HTR2B 4452/4885HTR2A 4386/4885HTR2C 4431/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 HTR2B 4374/4885HTR2A 4406/4885HTR2C 4269/4885
US-20090054644-A1 PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS OPRL1, OPRD1, OPRK1 HTR2B 62/4885HTR2A 146/4885HTR2C 44/4885
US-20080269208-A1 Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders SLC6A3, NDUFS5, NDUFB6 HTR2B 245/4885HTR2A 610/4885HTR2C 228/4885
US-20210188857-A1 SOS1 INHIBITORS SOS1, SOS2, SOST HTR2B 4452/4885HTR2A 4386/4885HTR2C 4431/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST HTR2B 4452/4885HTR2A 4386/4885HTR2C 4431/4885
US-20080045718-A1 Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives PDE4B, PDE4A, PDE3B HTR2B 1554/4885HTR2A 2267/4885HTR2C 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.